With Amazon in the wings, J&J retains dominant lead in pharma

10 July 2018

Amazon's (Nasdaq: AMZN) acquisition of PillPack will be troubling to big pharma executives throughout the industry, with the company having such vast existing revenue streams that it could outspend many of the sector's existing inhabitants.

The only company on the scale of Amazon to make a home in the pharma industry is Johnson & Johnson (NYSE: JNJ), which as a healthcare behemoth topped the charts for the largest companies by market capitalization once again despite suffering a noticeable decline of more than 10% last year, according to a new report from analystics firm GlobalData.

Pfizer's (NYSE:PFE) fortunes were very much the inverse — a pharma-focused company and smaller in overall revenues than J&J, but hitting its stride excellently and growing at a strong clip over the course of the last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK